AIM ImmunoTech enters amended research agreement with Roswell Park for Ampligen® studies

AIM ImmunoTech Inc.

Agreement covers three clinical trials: melanoma, prostate cancer, triple-negative breast cancer.
AIM will supply Ampligen® to Roswell Park for research projects at no cost.
Term is three years from September 20, 2023, or until completion of research.
Research may be funded by external entities (NIH, DOD, foundations); no financial terms disclosed.
AIM retains ownership of Ampligen® and pre-existing IP; jointly developed inventions are shared.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AIM ImmunoTech Inc. entered into Amended and Restated Material Transfer and Research Agreement with Roswell Park Cancer Institute Corporation d/b/a Roswell Park Comprehensive Cancer Center (effective 2023-09-28).

Action: entry
Agreement: collaboration
Counterparty: Roswell Park Cancer Institute Corporation d/b/a Roswell Park Comprehensive Cancer Center
Effective: 2023-09-28

Exact text from the filing

On September 28, 2023, AIM ImmunoTech Inc. (the “Company”) executed an Amended and Restated Material Transfer and Research Agreement (the “Agreement”) with Roswell Park Cancer Institute Corporation d/b/a Roswell Park Comprehensive Cancer Center (“Roswell”) that amends and restates the prior related agreements.

View on SEC.gov

623 material agreements filed in the last 30 days. Browse all material agreements →

AIM ImmunoTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-034740

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.